Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

References for PMC Articles for PubMed (Select 23277767)

1.

A unique researcher identifier for the Physician Payments Sunshine Act.

Carpenter D, Joffe S.

JAMA. 2011 May 18;305(19):2007-8. doi: 10.1001/jama.2011.651. No abstract available.

2.

"Off-label" indications for oncology drug use and drug compendia: history and current status.

[No authors listed]

J Oncol Pract. 2005 Sep;1(3):102-5. No abstract available.

3.

Off-label cancer drug compendia found outdated and incomplete.

Mitka M.

JAMA. 2009 Apr 22;301(16):1645-6. doi: 10.1001/jama.2009.536. No abstract available.

PMID:
19383947
4.

Systematic review: reliability of compendia methods for off-label oncology indications.

Abernethy AP, Raman G, Balk EM, Hammond JM, Orlando LA, Wheeler JL, Lau J, McCrory DC.

Ann Intern Med. 2009 Mar 3;150(5):336-43. Epub 2009 Feb 16. Review. Erratum in: Ann Intern Med. 2009 Apr 21;150(8):571.

PMID:
19221366
5.

Self-reported practices and attitudes of US oncologists regarding off-protocol therapy.

Peppercorn J, Burstein H, Miller FG, Winer E, Joffe S.

J Clin Oncol. 2008 Dec 20;26(36):5994-6000. doi: 10.1200/JCO.2008.18.1420. Epub 2008 Nov 24.

6.

From off-label prescribing towards a new FDA.

Tabarrok A.

Med Hypotheses. 2009 Jan;72(1):11-3. doi: 10.1016/j.mehy.2008.08.009. Epub 2008 Oct 2.

PMID:
18835103
7.

The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO).

Casali PG; Executive Committee of ESMO.

Ann Oncol. 2007 Dec;18(12):1923-5. No abstract available.

8.

Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels.

Gondek K, Sagnier PP, Gilchrist K, Woolley JM.

J Clin Oncol. 2007 Nov 10;25(32):5087-93. Review.

PMID:
17991926
9.

Reimbursement for cancer treatment: coverage of off-label drug indications.

American Society of Clinical Oncology.

J Clin Oncol. 2006 Jul 1;24(19):3206-8. Epub 2006 May 22.

10.

Off-label prescribing among office-based physicians.

Radley DC, Finkelstein SN, Stafford RS.

Arch Intern Med. 2006 May 8;166(9):1021-6.

PMID:
16682577
11.

Pharmaceutical industry sponsorship and research outcome and quality: systematic review.

Lexchin J, Bero LA, Djulbegovic B, Clark O.

BMJ. 2003 May 31;326(7400):1167-70. Review.

12.

Effect of off-label use of oncology drugs on pharmaceutical costs: the rituximab experience.

Kocs D, Fendrick AM.

Am J Manag Care. 2003 May;9(5):393-400; quiz 401-2.

13.

Scope and impact of financial conflicts of interest in biomedical research: a systematic review.

Bekelman JE, Li Y, Gross CP.

JAMA. 2003 Jan 22-29;289(4):454-65. Review.

PMID:
12533125
14.

Reporting of 6-month vs 12-month data in a clinical trial of celecoxib.

Hrachovec JB, Mora M.

JAMA. 2001 Nov 21;286(19):2398; author reply 2399-400. No abstract available.

PMID:
11712924
15.

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS.

JAMA. 2000 Sep 13;284(10):1247-55.

PMID:
10979111
16.

Unlicensed uses for medication in a palliative care unit.

Atkinson CV, Kirkham SR.

Palliat Med. 1999 Mar;13(2):145-52.

PMID:
10474697
17.

Reimbursement policies constrain the practice of oncology.

Laetz T, Silberman G.

JAMA. 1991 Dec 4;266(21):2996-9. Erratum in: JAMA 1992 Jun 24;267(24):3287.

PMID:
1820471
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk